Together with the observation that plasma GFAP levels are associated both with severity of AD pathology and manifestation of AD symptoms, they indicate that experimental treatments targeting reactive astrocytosis may be promising candidate AD therapies. The gene discussed is GFAP; the disease is Alzheimer disease.